Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer

Lung Cancer

Volumn 69, Issue 1, 2010, Pages 46-50

  Mathieu, Anne ^a   Weynand, Birgit ^b   Verbeken, Eric ^c   Da Silva, Susana ^d   Decaestecker, Christine ^e   Salmon, Isabelle ^a   Demetter, Pieter ^a  

^a ERASME HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NV Roche SA   (Belgium)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

EGFR; Epidermal growth factor receptor; Erlotinib; Immunohistochemistry; Lung cancer; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; BELGIUM; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STANDARDIZATION; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; ECONOMICS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; PROCEDURES; REIMBURSEMENT; REPRODUCIBILITY; STANDARDS;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; INSURANCE, HEALTH, REIMBURSEMENT; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS;

EID: 77953362638     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.09.003     Document Type: Article

References (32)

1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
3. Reck M., Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009, 63:1-9.
4. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
5. Metro G., Finocchiaro G., Capuzzo F. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Ann Oncol 2006, 17(Suppl. 2):ii42-ii45.
6. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Eng J Med 2005, 353:123-132.
7. Dancey J.E. Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow. Cancer Cell 2004, 5:411-415.
8. Parra H.S., Cavina R., Latteri F., Zucali P.A., Campagnoli E., Morenghi E., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa' ZD1839) in non-small-cell lung cancer. Br J Cancer 2004, 91:208-212.
9. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
10. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
11. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005, 16:538-548.
12. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
13. Italiano A., Burel Vandenbos F., Otto J., Mouroux J., Fontaine D., Marcy P.Y., et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 2006, 17:981-985.
14. Mukohara T., Kudoh S., Matsuura K., Yamauchi S., Kimura T., Yoshimura N., et al. Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC. Anticancer Res 2004, 24:11-17.
15. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3:515-522.
16. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Instit 2005, 97:643-655.
17. Scagliotti G.V., Selvaggi G., Novello S., Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004, 10:4227s-4232s.
18. Buckley A.F., Kakar S. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2007, 15:305-309.
19. Penault-Llorca F., Cayre A., Arnould L., Bibeau F., Bralet M.P., Rochaix P., et al. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?. Oncol Rep 2006, 16:1173-1179.
20. Meert A.P., Martin B., Verdebout J.M., Paesmans M., Berghmans T., Ninane V., et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004, 44:295-301.
21. Suzuki S., Dobashi Y., Sakurai H., Nishikawa K., Hanawa M., Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005, 103:1265-1273.
22. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006, 1:19.
23. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
24. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med 2004, 350:2129-2139.
25. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
26. Sakurada A., Shepherd F.A., Tsao M.S. Epidermal growth factor tyrosine kinase inhibitors in lung cancer: Impact of primary or secondary mutations. Clin Lung Cancer 2006, 7:S138-S144.
27. Joshi A.S., Sharangpani G.M., Porter K., Keyhani S., Morrison C., Basu A.S., et al. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A 2007, 71:273-285.
28. Aviel-Ronen S., Blackhall F.H., Shepherd F.A., Tsao M.S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006, 8:30-38.
29. Wheatley-Price P., Shepherd F.A. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008, 20:162-175.
30. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
31. Pesek M., Benesova L., Belsanova B., Mukensnabl P., Bruha F., Minarik M. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009, 29:2767-2773.
32. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with our without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.